These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30622959)

  • 1. Corrigendum to "Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate".
    Rabe T; Saenger N; Ebert AD; Roemer T; Tinneberg HR; De Wilde RL; Wallwiener M
    Biomed Res Int; 2018; 2018():6124628. PubMed ID: 30622959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of selective progesterone receptor modulators for the treatment of uterine fibroids.
    Bestel E; Donnez J
    Expert Rev Endocrinol Metab; 2014 Jan; 9(1):79-92. PubMed ID: 30743741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
    Talaulikar VS; Manyonda I
    Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
    Singh SS; Belland L; Leyland N; von Riedemann S; Murji A
    Am J Obstet Gynecol; 2018 Jun; 218(6):563-572.e1. PubMed ID: 29274830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?
    Pourcelot AG; Capmas P; Fernandez H
    J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):249-254. PubMed ID: 28403922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.
    Rabe T; Saenger N; Ebert AD; Roemer T; Tinneberg HR; De Wilde RL; Wallwiener M
    Biomed Res Int; 2018; 2018():1374821. PubMed ID: 30539001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
    Donnez J; Donnez O; Dolmans MM
    Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ulipristal acetate for uterine fibroid-related symptoms.
    Puchar A; Luton D; Koskas M
    Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
    Brazert M; Korman MP; Pawelczyk LA
    Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.
    Garnock-Jones KP; Duggan ST
    Drugs; 2017 Oct; 77(15):1665-1675. PubMed ID: 28900897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
    Szamatowicz M; Kotarski J
    Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of ulipristal acetate in female patients with uterine fibroids.
    Grzechocinska B; Gadomska H; Zygula A; Wielgos M
    Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging treatment options for uterine fibroids.
    Donnez J; Arriagada P; Donnez O; Dolmans MM
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):17-23. PubMed ID: 29486606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
    Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
    Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
    Ferrero S; Vellone VG; Barra F
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
    Pérez-López FR
    Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids.
    Ali M; Al-Hendy A
    Biol Reprod; 2017 Sep; 97(3):337-352. PubMed ID: 29025038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids.
    Bouchard P; Chabbert-Buffet N
    Best Pract Res Clin Obstet Gynaecol; 2017 Apr; 40():105-110. PubMed ID: 28169130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
    Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
    Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis.
    Zakiyah N; van Asselt AD; Postma MJ
    J Med Econ; 2017 Mar; 20(3):280-287. PubMed ID: 27786570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.